ZVRAHealthcare · BiotechnologyThe 9 Wall Street analysts covering Zevra Therapeutics, Inc. hold a median 12-month price target of $24 — +112.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Zevra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ZVRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +112.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $24 → $23 |
| 6 Aug 2026 | Citizens | Maintains | Market Outperform | $25 → $28 |
| 27 July 2026 | BTIG | Maintains | Buy | — |
| 27 July 2026 | BTIG | Maintains | Buy | $27 → $24 |
| 27 July 2026 | Canaccord Genuity | Maintains | Buy | $29 → $20 |
| 27 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 July 2026 | Guggenheim | Maintains | Buy | $29 → $24 |
| 27 July 2026 | Guggenheim | Maintains | Buy | — |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $26 |
| 23 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 June 2026 | Guggenheim | Maintains | Buy | — |
| 10 June 2026 | Maxim Group | Maintains | Buy | — |
| 9 June 2026 | BTIG | Reiterates | Buy | — |
| 9 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 9 June 2026 | Citizens | Maintains | Market Outperform | — |
| 8 June 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 8 May 2026 | Guggenheim | Maintains | Buy | — |
| 16 Mar 2026 | BTIG | Initiates | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZVRA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 54% of US stocks
Cheaper than 26% of US stocks
Cheaper than 33% of US stocks
Cheaper than 35% of US stocks
Higher than 87% of US stocks
Higher than 4% of US stocks
Higher than 99% of US stocks
Higher than 93% of US stocks
Higher than 95% of US stocks
Higher than 90% of US stocks
Higher than 90% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Zevra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zevra Therapeutics reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
Why it matters — The substantial year-over-year revenue increase, led by MIPLYFFA sales, signals growing commercial traction for Zevra's key treatment.
Zevra Therapeutics held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the event. The transcript covers the company's quarterly results and management discussion as presented during the call.
Why it matters — ZVRA watchers can review the transcript for management commentary and details on the company's second-quarter 2026 performance directly from the call.
Zevra Therapeutics reported Q2 earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $1.21 per share in the same quarter a year ago, and the company's revenues also surpassed estimates.
Why it matters — The earnings and revenue beat relative to analyst expectations signals stronger-than-anticipated quarterly results for Zevra Therapeutics, which is relevant to those tracking the stock.
Zevra Therapeutics reported its second quarter 2026 financial results, with $39.7 million in net revenue driven by $30.2 million from MIPLYFFA, a 53% increase over Q2 2025. The company also reported a strong cash position of $260.2 million and scheduled a conference call for August 5, 2026.
Why it matters — The substantial year-over-year revenue growth and strong cash position signal continued commercial momentum for MIPLYFFA and financial stability for the company.
Zevra Therapeutics announced that members of its executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on August 11, 2026 at 11:00 a.m. ET. Management will also be available for one-on-one meetings with registered conference attendees.
Why it matters — A ZVRA watcher would care because it signals an opportunity for investors and analysts to hear directly from the company's executive leadership at a major industry growth conference.
The 9 Wall Street analysts covering Zevra Therapeutics, Inc. have a median 12-month price target of $24, with estimates ranging from $20 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Zevra Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zevra Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Zevra Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +112.0% from the last close, and Ticker Nerd's factor model ranks Zevra Therapeutics, Inc. 97 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Zevra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $35 over the next 12 months.
Zevra Therapeutics, Inc. returned +27.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treatments for rare diseases.
The most recent item we track (MarketBeat, 6 Aug 2026): "Zevra Therapeutics Q2 Earnings Call Highlights". Zevra Therapeutics reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on treatments for rare diseases. The company concentrates on rare neurological and sleep-related conditions, including certain urea cycle disorders, Niemann-Pick disease type C, and idiopathic hypersomnia. Zevra Therapeutics develops and commercializes therapies aimed at patient populations with limited or no existing treatment options, emphasizing data-driven development and close alignment with patient needs. In addition to its internal pipeline, the company participates in the rare disease market through royalty revenue associated with AZSTARYS, an attention-deficit/hyperactivity disorder (ADHD) treatment marketed by a commercial partner. Headquartered in Celebration, Florida and founded in 2006, Zevra Therapeutics operates within the broader health technology and pharmaceuticals industry, serving specialized healthcare providers, treatment centers, and patients affected by complex, underserved conditions. Its role in the market is defined by a focus on niche indications where regulatory pathways and clinical development require targeted expertise and close collaboration with the rare disease community.
CEO Mr. Neil F. McFarlane · 61 employees · United States · https://www.zevra.com